Search

CytomX Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

3.69

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.52

Max

3.71

Galvenie mērījumi

By Trading Economics

Ienākumi

8.3M

-18M

Pārdošana

9.6M

10M

P/E

Sektora vidējais

22.5

60.149

EPS

-0.1

Peļņas marža

-177.89

Darbinieki

69

EBITDA

9.5M

-18M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+221.47% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 6. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-91M

819M

Iepriekšējā atvēršanas cena

3.69

Iepriekšējā slēgšanas cena

3.69

Ziņu noskaņojums

By Acuity

60%

40%

289 / 342 Rangs Healthcare

CytomX Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 16. jūl. 23:52 UTC

Social Media
News

Netflix Inc. shares fell in after-hours trading following Q2 results. Revenue of $12.56 billion missed expectations, and guidance for 2026 was narrowed lower.

2026. g. 16. jūl. 23:46 UTC

News

Paychex declared a quarterly dividend of $1.19 per share, payable August 28, contributing to positive sentiment as shares rise in after-market trading.

2026. g. 16. jūl. 23:46 UTC

ETF Constituents
News
Correlated Moves

Vanguard Growth ETF declines after-hours, impacted by Netflix's drop and broader Nasdaq 100 downturn amid rising inflation concerns and central bank comments.

2026. g. 16. jūl. 23:41 UTC

News
Correlated Moves

Lam Research Corp shares are lower in after-market trading amid a sector-wide selloff following TSMC's capital expenditure announcement and bearish sentiment from options traders.

2026. g. 16. jūl. 23:36 UTC

News

T-Mobile US Inc. experienced routine after-market trading with little change since Thursday's close, maintaining its focus on versatile mobile internet plans.

2026. g. 16. jūl. 23:31 UTC

News
Correlated Moves

Micron Technology shares declined in after-market trading amid negative sentiment in the tech sector and concerns over rising capital costs from TSMC.

2026. g. 16. jūl. 23:21 UTC

News
Social Media

PayPal Holdings Inc. shares are lower in after-market hours as its board deems a $53 billion takeover bid from Stripe inadequate amid broader market declines.

2026. g. 16. jūl. 23:16 UTC

Correlated Moves
News

Intuit Inc shares are lower in after-market trading following a class action lawsuit alleging overstated revenue growth and competitive advantages. Concerns about layoffs persist.

2026. g. 16. jūl. 23:16 UTC

News
Social Media

Alphabet Inc shares are higher in after-market trading, rebounding from earlier session lows. Concerns persist over delays in the rollout of its Gemini AI.

2026. g. 16. jūl. 23:06 UTC

News

United Airlines Holdings Inc shares are lower in after-market hours, reflecting broader market declines amid concerns over major tech stocks and geopolitical risks.

2026. g. 16. jūl. 23:02 UTC

News
Social Media

Intuitive Surgical shares fell in after-market trading despite strong earnings, as management cited U.S. market challenges and a Class II recall of surgical components.

2026. g. 16. jūl. 23:01 UTC

News

Escalating military tensions in the Middle East are impacting the United States Oil Fund LP, which is trading lower during after-market hours.

2026. g. 16. jūl. 23:01 UTC

News
ETF Constituents
Correlated Moves
Macro News

Vanguard Information Technology ETF declines after major indices drop, led by weakness in semiconductor stocks and a significant decline in Netflix shares.

2026. g. 16. jūl. 23:01 UTC

News

Fiserv Inc. shares are lower in after-market trading amid operational challenges, including a 2% revenue decline and a significant drop in operating income.

2026. g. 16. jūl. 20:07 UTC

News

Spot silver prices are higher today, despite earlier pulling back from a session high, amid escalating U.S.-Iran tensions and rising inflation concerns.

2026. g. 16. jūl. 20:07 UTC

News
Correlated Moves

CHF/HKD is trading lower as initial jobless claims fall to a two-month low, indicating labor market strength amid rising geopolitical tensions.

2026. g. 16. jūl. 20:06 UTC

News
Correlated Moves

Gold prices are lower as inflation risks rise amid the U.S.-Iran conflict. Earlier, gold peaked at $3,992.10 per ounce before declining.

2026. g. 16. jūl. 20:06 UTC

News
Correlated Moves

Spot silver prices are declining amid rising U.S.-Iran tensions and inflation concerns, currently trading around $56.82 per ounce. Gold also fell sharply today.

2026. g. 16. jūl. 20:06 UTC

Macro Event
Correlated Moves
News

Xcel Energy shares are higher, supported by analysts' positive ratings adjustments and a favorable move in the Electric Utilities sub-sector.

2026. g. 16. jūl. 20:06 UTC

Correlated Moves
News

Spot silver prices are lower today, trading around $56.82 per ounce amid rising inflation concerns and expectations for Federal Reserve rate hikes.

2026. g. 16. jūl. 20:06 UTC

News
Correlated Moves

Spot silver prices are declining amid rising U.S.-Iran tensions and inflation concerns. The metal is trading near $56.82 per ounce, reflecting broader weakness in precious metals.

2026. g. 16. jūl. 20:06 UTC

News
Correlated Moves

Spot silver prices are declining amid rising U.S.-Iran tensions and inflation concerns, trading around $56.82 per ounce after a significant drop since Wednesday.

2026. g. 16. jūl. 20:06 UTC

Correlated Moves
News

Spot silver prices are lower, trading around $56.82 per ounce amid rising U.S.-Iran tensions and inflation concerns. Gold also declined significantly today.

2026. g. 16. jūl. 20:06 UTC

Correlated Moves
News

Spot silver prices are lower today, trading around $56.82 per ounce amid rising inflation concerns and expectations for Federal Reserve rate hikes.

2026. g. 16. jūl. 20:06 UTC

Correlated Moves
News

GBP/HKD is trading lower amid the Bank of Korea's interest rate hike to 2.75%. The currency pair reached a session low following early gains.

2026. g. 16. jūl. 20:03 UTC

Correlated Moves
News

Wedbush initiated coverage on Verisign with an Outperform rating. Shares are gaining today, reflecting positive sentiment after closing at $268.85.

2026. g. 16. jūl. 20:03 UTC

News

O'Reilly Automotive advances amid speculation of a $10 billion acquisition of Genuine Parts' auto parts unit, with analysts citing potential benefits despite FTC review concerns.

2026. g. 16. jūl. 20:03 UTC

Correlated Moves
Social Media
News

Qualcomm Inc shares are lower as the semiconductor sector faces pressure from Micron Technology's supply agreements and a notable decline in the Nasdaq 100 Index.

2026. g. 16. jūl. 20:02 UTC

News

Align Technology Inc. reported first-quarter revenue of $1.00 billion, slightly above expectations, but shares are lower amid broader market unease and geopolitical tensions.

2026. g. 16. jūl. 19:56 UTC

News
Social Media

Expedia Group shares rise after Wedbush initiated coverage with an Outperform rating and a price target of $334, indicating growth potential.

Salīdzinājums

Cenas izmaiņa

CytomX Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

221.47% augšup

Prognoze 12 mēnešiem

Vidējais 11.83 USD  221.47%

Augstākais 16 USD

Zemākais 6 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

6

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

289 / 342 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
help-icon Live chat